Suppliers and packagers for attruby

attruby

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bridgebio Pharma	ATTRUBY	acoramidis hydrochloride	TABLET;ORAL	216540	NDA	BridgeBio Pharma, Inc.	82228-712-28	4 DOSE PACK in 1 CARTON (82228-712-28) / 1 BLISTER PACK in 1 DOSE PACK / 28 TABLET, FILM COATED in 1 BLISTER PACK	2024-11-22

Suppliers for the Pharmaceutical Drug: ATTRUBY

Last updated: July 30, 2025

Introduction

ATTRUBY (Generic name: Pevonedistat) represents a novel class of anti-cancer agents, specifically targeting NEDD8-activating enzyme (NAE), crucial for regulating the ubiquitin-proteasome system. Approved by regulatory agencies like the FDA for specific indications such as acute myeloid leukemia (AML), ATTRUBY's market success hinges significantly on its supply chain robustness and the reliability of its suppliers. This article examines the key suppliers involved in the manufacturing and distribution of ATTRUBY, exploring their roles, capacities, and strategic importance for stakeholders in the pharmaceutical ecosystem.

Manufacturing and Synthesis of ATTRUBY

ATTRUBY's active pharmaceutical ingredient (API), pevonedistat, is synthesized through a complex multi-step process requiring specialized chemical expertise and high-quality raw materials. The synthesis involves proprietary starting materials and intermediates supplied by a select group of global chemical and pharmaceutical suppliers. These raw materials must meet rigorous purity standards, adhering to Good Manufacturing Practice (GMP) regulations.

Key Raw Material Suppliers

The production of pevonedistat depends on several critical raw materials, including:

• Nedd8 pathway intermediates: These compounds are fundamental to the API's mechanism of action. Suppliers of these intermediates are often specialized chemical firms with patented processes.
• Reagents and solvents: High-purity solvents and reagents such as acetonitrile, dimethylformamide (DMF), and others are sourced primarily from leading bulk chemical companies.

Leading suppliers typically include major global chemical manufacturers like Merck KGaA, BASF, and Sigma-Aldrich (a subsidiary of Merck), which provide pharmaceutical-grade materials meeting stringent quality standards.

API Manufacturers

The API for ATTRUBY, pevonedistat, is produced by a limited number of authorized manufacturing organizations, often under exclusive or semi-exclusive licensing agreements. Key API manufacturers tangentially involved include:

• CStone Pharmaceuticals: A Chinese biopharmaceutical company that has invested in the development and manufacturing of pevonedistat, especially under collaboration agreements with the original innovators. CStone holds manufacturing rights in certain territories and has scaled production capacity to meet global demand.

• Auriga Laboratories and Chinese Contract Manufacturing Organizations (CMOs): Several CMOs in Asia, primarily in China and India, have obtained technology transfer rights to manufacture pevonedistat for regional markets, given the cost advantages and capacity expansions.

• PrimeVaccine and Delin Gene provide contract manufacturing services for active molecules, demonstrating the global shift toward outsourcing API production to enhance scalability and reduce costs.

Formulation and Finished Dosage Suppliers

Once the API is produced, formulation specialists convert pevonedistat into the finished injectable form used clinically. Major pharmaceutical contract manufacturers involved include:

• Catalent Inc.: Known for sterile fill-finish capabilities, Catalent supplies the final ATTRUBY formulations to various markets, leveraging existing infrastructure for expedited commercialization.

• Patheon (a part of Thermo Fisher Scientific): Provides formulation, sterile manufacturing, and packaging service, ensuring compliance with international standards.

Distribution and Supply Chain Logistics

Ensuring the stability of the supply chain for ATTRUBY involves a network of:

• Cold chain logistics providers such as DHL and FedEx Custom Critical, providing temperature-controlled transportation critical for preserving API and final product integrity.
• Global distribution partners: Major pharmaceutical distributors like McKesson and Cardinal Health are instrumental in distributing ATTRUBY, especially in North America and Europe.

Strategic and Market Implications

The suppliers of ATTRUBY's raw materials and finished product are key to its market stability. Dependence on specialized chemical suppliers and contract manufacturers introduces supply chain vulnerabilities, especially amid geopolitical tensions and global supply disruptions.

Most manufacturers operate under strict quality and regulatory oversight by authorities such as the FDA, EMA, and China’s NMPA, ensuring compliance but also creating barriers to new entrants.

Emerging Trends and Future Supply Considerations

• Diversification of supply sources: To mitigate risks, pharmaceutical companies are increasingly diversifying suppliers across geographies.
• Vertical integration: Some firms may pursue integrated manufacturing, controlling raw materials, API synthesis, and formulation stages to ensure supply continuity.
• Innovations in synthesis and raw materials: Continuous research can reduce dependency on scarce intermediates, fostering more resilient supply chains.

Conclusion

The supply chain for ATTRUBY is characterized by a small but global network of specialized raw material suppliers, contract manufacturers, and logistics providers. While current suppliers include prominent chemical and pharmaceutical manufacturing firms such as Merck KGaA, Sigma-Aldrich, CStone Pharmaceuticals, Catalent, and Patheon, the inherent complexities necessitate strategic supply chain management to prevent disruptions. As the drug gains wider indications and market penetration, supplier relationships and diversification strategies will become increasingly vital for sustained availability.

---

Key Takeaways

• The production of ATTRUBY relies on a limited pool of high-quality chemical suppliers, API manufacturers, and formulation specialists, emphasizing the importance of supply chain security.
• Diversification and vertical integration are emerging strategies to mitigate risks associated with raw material shortages and manufacturing bottlenecks.
• Contract manufacturing organizations (CMOs) play a pivotal role in scaling production and ensuring compliance with global regulatory standards.
• Cold chain logistics are critical for maintaining the stability of the API and finished drug during transportation.
• Monitoring geopolitical and trade policies is crucial, as they can significantly impact the supply chain resilience of ATTRUBY.

---

FAQs

Q1: Who are the primary raw material suppliers for ATTRUBY’s API?
The main raw material suppliers include pharmaceutical-grade chemical companies like Sigma-Aldrich (Merck), BASF, and specialized intermediates manufacturers providing critical reagents used in pevonedistat synthesis.

Q2: Which companies manufacture the active pharmaceutical ingredient (API) for ATTRUBY?
CStone Pharmaceuticals, along with regional CMOs in China and India, are key API manufacturers, often under licensing agreements designed to expand regional supply capacity.

Q3: Are there risks associated with the current supply chain for ATTRUBY?
Yes, reliance on a limited number of specialized suppliers and geopolitical factors increase the risks of supply disruptions, prompting strategies like diversification to mitigate these vulnerabilities.

Q4: How is the finished ATTRUBY product formulated and distributed?
Formulation is handled by CDMOs such as Catalent and Patheon, while distribution relies on global logistics providers like DHL and major pharmaceutical distributors for widespread clinical and commercial use.

Q5: What future developments could impact the supply chain of ATTRUBY?
Advances in synthesis methods, raw material sourcing, increased regional manufacturing, and shifts in geopolitical landscapes could influence supply chain stability and scalability.

---

References

1. U.S. Food and Drug Administration (FDA). "ATTRUBY (Pevonedistat) approval details." Accessed 2023.
2. ClinicalTrials.gov. "Studies involving pevonedistat." Registry data.
3. Industry reports on pharmaceutical contract manufacturing and supply chain trends (e.g., IQVIA, EvaluatePharma).
4. Company websites: Merck KGaA, CStone Pharmaceuticals, Catalent, Patheon.
5. Global trade and logistics provider reports on cold chain distribution.